Author: Jennifer Levy

2019 was a busy year for Coalition to Cure Calpain 3! During the past year we: • Funded two new research projects: Funding was awarded to Dr. Jaakko Sarparanta, Folkhälsan Research Center and the University of Helsinki, and Dr. Nicholas

Promising Insights into Safety of LGMD2A/R1 Gene Therapy Approach

Published research alert: Titin splicing regulates cardiotoxicity associated with Calpain-3 gene therapy for LGMD2A/R1 Coalition to Cure Calpain 3 (C3) is pleased to announce the publication of research undertaken by Dr. Isabelle Richard, Head of the Progressive Dystrophy Laboratory, Généthon,

Double your donation on Giving Tuesday 2019

A “C3 Champion” has made a commitment to match every dollar donated on Giving Tuesday, up to $25,000. Your contribution today to support scientific research for those families impacted by the muscle-wasting disease LGMD2A/R1 (a form of calpainopathy)

C3 Scientific Director Dr. Jennifer Levy Appointed to Muscular Dystrophy Coordinating Committee

The Muscular Dystrophy Coordinating Committee (MDCC) is a federal advisory committee that aims to coordinate the activities repeated to muscular dystrophy research across the National Institutes of Health (NIH) and other federal programs including the Centers for Disease Control and

2019 World Muscle Society Recap

The 24th International Annual Congress of the World Muscle Society was held October 1-5, 2019 in Copenhagen, Denmark. C3 Scientific Director Dr. Jennifer Levy represented Coalition to Cure Calpain 3 (C3) and presented a poster detailing the C3 mission, patient

An LGMD by any other name … is still an LGMD: New nomenclature for the LGMDs

Those who recently attended the National LGMD Conference in Chicago learned that the LGMDs are getting new names. In the old naming system, dominant LGMDs were called LGMD1s and recessive LGMDs were called LGMD2s. The subtypes were further delineated

New resource to learn about clinical research opportunities for LGMD2A

Are you or a family member with LGMD2A interested in participating in clinical research studies or trials? Click here to view C3’s new Clinical Research Opportunity Resource Center to learn more about clinical research and current opportunities to participate. This

University of Florida College of Medicine Study Recruiting LGMD2A Patients Living in the Southeast U.S. and Texas

Individuals with LGMD2A, a form of calpainopathy, are being sought for a Magnetic Resonance Imaging (MRI) and Spectroscopy (MRS) study. Please direct any questions related to this study, including participation guidelines and aims, to Dr. Glenn Walter, University of Florida

Published Research Alert: Gene Correction of LGMD2A Specific iPSCs for the Development of Targeted Autologous Cell Therapy

Coalition to Cure Calpain 3 (C3) is pleased to announce the publication of important research undertaken by Dr. Rita Perlingeiro, Professor of Medicine, University of Minnesota, and colleagues. The paper, titled “Gene Correction of LGMD2A Specific iPSCs for the Development of Targeted Autologous

Together we are STRONGER: 5th Annual LGMD Awareness Day is Coming Up!

The 5th annual Limb Girdle Muscular Dystrophy Awareness Day is coming up on September 30, 2019. Help C3 raise awareness of LGMD in your community and through social media. It’s time to: 1. Start planning to wear Lime Green on